Genera is a spin-off of the Walter and Eliza Hall Medical Research Institute, Australia’s leading research institute, and is a publicly traded company (ASX: GBI) that develops and markets proprietary, multiplexed molecular diagnostic tests Pearl-based AmpaSand. technology.
Genera’s products compete in the global market for molecular diagnostic tests (currently valued at around US $ 5.3 billion and expected to double in the next five years) and are used by commercial pathology providers. AmpaSand beads are an ideal platform for the type of medium density multiplexed tests (5-150 analytes) most useful in pathology laboratories.
We are committed to providing clinically relevant and accurate molecular diagnostic assays to physicians and their patients.